10 results
• To assess the effect of lorazepam compared to placebo on stability (Body Sway) in relation to stabilizing subsystems (BalRoom) in healthy elderly.• To assess the effect of haloperidol compared to placebo on stability (Body Sway) in relation to…
Primary objective(s):To evaluate the effect of early haloperidol prophylaxis on the incidence, severity and duration of in-hospital delirium in at-risk patients aged 70 years and over who are acutely admitted to the hospital through the ED, for…
In this study we aim to examine the effects of a low dosage of prophylactic haloperidol in patients with an expected ICU length of stay of >1 day. We use two different dosages of haloperidol in this study to compare with placebo. A dosage of…
In this study, we aim to improve recognition of delirium in a palliative care population with advancedcancer and we aim to provide evidence for optimal treatment of delirium through adequate dosing ofpreferred neuroleptic.Primary objectives:1) To…
This study aims to clarify whether the brain dopamine and noradrenaline system underlie the electrocortical responses (event-related potentials) that are sensitive to cues signalling reward and probability, the P200 and P300.
The primary objective of this study is to test the hypothesis that discontinuation of antipsychotics does not lead to deterioration in functioning as measured by the ABC.
The role of dopamine in bias and disengagement, two mechanisms implicated in visuospatial attention.
To gain insight in the role of the dopaminergic system in two components of visuospatial attention, bias and disengagement.
To study whether rivastigmine added to treatment with haloperidol shortens the duration of delirium in ICU patients and reduces costs.
The aim of this study is to determine whether LNP023 is effective and safe for the treatment of PNH. LNP023 is compared to the Standard of Care (SOC) anti-C5 antibody treatment. The primary objectives are to:• Demonstrate superiority of LNP023…
The primary objective of this study is to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, andefficacy of ALXN1210 in pediatric patients with paroxysmal nocturnal hemoglobinuria (PNH).